

The Characteristics of Metallo- β -Lactamase-Producing Gram-Negative Bacilli Isolated from Sputum and Urine: A Single Center Experience in Korea

Bum Sik Chin,¹ Sang Hoon Han,¹ Suk Hoon Choi,¹ Han Sung Lee,¹ Su Jin Jeong,¹ Hee Kyung Choi,¹
Jun Yong Choi,¹ Young Goo Song,¹ Chang Ki Kim,² Dongeun Yong,²
Kyungwon Lee,² and June Myung Kim¹

¹AIDS Research Institute and Department of Internal Medicine, Yonsei University College of Medicine, Seoul;

²Research Institute of Bacterial Resistance and Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.

Received: May 26, 2009

Revised: September 4, 2009

Accepted: September 7, 2009

Corresponding author: Dr. June Myung Kim,
Department of Internal Medicine,
Yonsei University College of Medicine,
250 Seongsan-ro, Seoul 120-752, Korea.
Tel: 82-2-2228-1946, Fax: 82-2-393-6884
E-mail: jmkim@yuhs.ac

The authors have no financial conflicts of interest.

Metallo- β -lactamase (MBL) production usually results in high-level resistance to most β -lactams, and a rapid spread of MBL producing major gram-negative pathogens is a matter of particular concern worldwide. However, clinical data are scarce and most studies compared MBL producer (MP) with MBL non-producer (MNP) strains which included carbapenem susceptible isolates. Therefore, we collected clinical data of patients in whom imipenem-nonsusceptible *Pseudomonas aeruginosa* (PA) and *Acinetobacter baumannii* (AB) were isolated from sputum or urine, and investigated MBL production and the risk factors related with MBL acquisition. The antimicrobial susceptibility patterns were also compared between MPs and imipenem-nonsusceptible MNPs (INMNP). Among the 176 imipenem-nonsusceptible isolates, 12 MPs (6.8%) were identified. There was no identifiable risk factor that contributed to the acquisition of MPs when compared to INMNPs, and case-fatality rates were not different between the two groups. The percentage of susceptible isolates was higher among MPs for piperacilin/tazobactam and fluoroquinolones while that of ceftazidime was higher in INMNPs ($p < 0.05$). As regards to aztreonam, which has been known to be a uniquely stable β -lactam against MBLs, susceptibility was preserved in only two isolates (16.7%) among MPs, and was not higher than that of INMNPs (23.2%). In conclusion, the contribution of MBLs to imipenem non-susceptibility in PA/ABs isolated from sputum and urine was relatively limited, and there was no significant risk factor associated with acquisition of MPs compared with INMNPs. However, limited susceptibility to aztreonam implies that MPs may hold additional resistance mechanisms, such as extended spectrum β -lactamases, AmpC β -lactamases, or other non-enzymatic mechanisms.

Key Words: Metallo- β -lactamase, risk factor, resistance

© Copyright:

Yonsei University College of Medicine 2011

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acquired carbapenemases represent a major threat to the clinical utility of all

β -lactam antibiotics. Particularly, the emergence of acquired metallo- β -lactamase (MBL) among major gram-negative pathogens [*Pseudomonas aeruginosa* (PA), *Acinetobacter* spp., *Enterobacteriaceae*] is a matter of particular concern on account of their rapid spread and increasing diversity/number of species involved.¹ However, limited clinical data are available regarding to the clinical significance of infections caused by these strains. Several studies have demonstrated that MBL producer (MP) acquisition is associated with increased mortality in PA infection.²⁻⁵ However, carbapenem susceptible strains are included in MBL non-producer (MNP) in most studies, thus revealing higher mortality in the MBL producing group. It is well known that acquisition of carbapenem resistance is associated with increased mortality in PA and *Acinetobacter baumannii* (AB) infections.^{6,7} Therefore, to characterize the MBL production itself rather than carbapenem resistance, we compared MBL producing PA/AB and imipenem-nonsusceptible MNPs (INMNP) isolated from respiratory and urinary tracts which are common sites of clinical infections and sources of nosocomial spread.

The microbiology laboratory database was reviewed, and we selected imipenem-nonsusceptible PA and AB which had been isolated from sputum or urine for the purpose of microbiologic diagnosis irrespective of hospitalization between January 2007 and June 2007 in a single 2,000-bed tertiary hospital in Seoul, Republic of Korea. Clinical data for the source patients of the isolates were collected by a retrospective analysis of the electronic medical records, and patients were excluded from the analysis if medical records prior to the isolation were not sufficient (e.g., transfer from another hospital). Patients without available follow-up data after discharge were also excluded from the analysis. Isolates referred from outpatient departments (OPD) were included if sufficient medical history was available. All the isolates that had been related with both clinical infections or colonization of the respiratory or urinary tracts were considered eligible for the study. Only the first isolate from each patient was included in the analysis.

The PA/AB strains were identified using conventional techniques and/or ATB 32 GN system (BioMérieux, Marcy-l'Étoile, France).⁸ The antimicrobial susceptibility was determined using a disk-diffusion method. Results were interpreted using the guidelines of the Clinical and Laboratory Standards Institute.⁹

Among the imipenem-nonsusceptible isolates, carbapenemase production was screened by the imipenem disk Hodge

(cloverleaf) test, using MacConkey agar instead of the previously used Mueller-Hinton agar.¹⁰ MBL production was screened by the double-disk synergy test using an imipenem disk and an EDTA (750 μ g) plus sodium mercaptoacetic acid (SMA, 2 mg) disk on Mueller-Hinton agar with 10 mm distance from the edge to the edge of the disk.¹⁰ Commercial imipenem disks and media (Becton-Dickinson, Sparks, MD, USA) were used for these tests, while the EDTA-SMA disks were prepared from commercially available chemicals (Sigma Chemical, St. Louis, MO, USA). The *bla*_{IMP-1}, *bla*_{VIM-2} and *bla*_{SIM-1} alleles were detected by polymerase chain reaction (PCR) among the screening positive isolates as described previously¹¹ and the primers used were: IMP1-F 5'-CAT GGT TTG GTG GTT CTT GT-3', IMP1-R 5'-ATA ATT TGG CGG ACT TTG GC-3', VIM2-F 5'-ATG TTC AAA CTT TTG AGT AAG-3', VIM2-R 5'-CTA CTC AAC GAC TGA GCG-3', SIM1-F 5'-TAC AAG GGA TTC GGC ATC G-3' and SIM1-R 5'-TAA TGG CCT GTT CCC ATG TG-3'.

To perform the pulsed field gel electrophoresis (PFGE), genomic DNA of MBL-producing PA and AB was digested with *Xba*I and *Sma*I, respectively, as suggested by the manufacturer. Fragments were separated for 20 hours at 6 V/cm at 11°C using a CHEF-DR II system (Bio-Rad, Hercules, CA, USA). ProMega-Markers Lambda Ladders G3011 (Promega, WI, USA) was used for molecular mass marker.

To identify risk factors contributing to MBL producer acquisition, we reviewed age, gender, Charlson index, APACHE II score, underlying illness, the entire hospital stay period including multiple admissions within six months prior to isolation, intensive care unit (ICU) stay, ventilator care, and antibiotics exposure prior to isolation such as piperacillin/tazobactam, cefoperazone/sulbactam, aztreonam, fluoroquinolones, aminoglycosides, glycopeptides, ceftazidime, and carbapenems. ICU stay, ventilator care and antibiotic exposure were included when each factor lasted more than 48 hours within 28 days prior to isolation. Neutropenia (absolute neutrophil count < 1,000 mm³), immunosuppression (administration of cytostatic agent or glucocorticoid equivalent or more potent than methylprednisolone 20 mg per day for more than 14 days), and antineoplastic treatment within 3 months prior to the isolation were also investigated. To assess the outcome, 28-day case-fatality after isolation and in hospital case-fatality were analyzed. Statistical analyses were performed by SAS version 9.1.3 (SAS Institute, Inc., Cary, NC, USA). All tests were two-tailed, and a *p* value < 0.05 was considered significant.

During the study period, 432 PA (340 from sputum and 92 from urine) and 199 AB (159 from sputum and 40 from urine) non-repetitive isolates were identified. Among them, 187 (29.6%) were imipenem non-susceptible (130 PA and 57 AB). Eleven isolates were excluded from the analysis because of inadequate availability of their medical records. Finally, 176 isolates consisting of 123 PA (102 from sputum and 21 from urine) and 53 AB (48 from sputum and 5 from urine) were analyzed. The proportion of sources (sputum and urine) was not different between PA and AB ($p = 0.19$, data not shown).

MBL production was identified in 12 isolates by PCR (6.8%)(Table 1). The bla_{VIM-2} was the most common MBL type (75%, 6 of 7 PA and 3 of 5 AB); two bla_{IMP-1} and one bla_{SIM-1} sequences were identified in MPs. The proportions of susceptible strains among MPs were 41.7% for piperacillin/tazobactam, fluoroquinolones, and aminoglycosides while few isolates proved to be susceptible to aztreonam (16.7%) and ceftazidime (8.3%). In PFGE analysis, 5 AB isolates revealed different patterns (Fig. 1). However, 2 isolates among the 7 MBL-producing PA revealed identical PFGE patterns. They were obtained 14 days apart from an inpatient of a rehabilitation center and an outpatient who was regularly visiting OPD of the same center. This last patient was the only one whose culture study was referred from OPD among the 176 imipenem nonsusceptible PA and AB isolates in our study. The proportion of MPs among imipenem non-susceptible isolates was not different according to the species (PA 5.7%/AB 9.4%). However, urine had higher proportion of MP among imipenem non-susceptible isolates than sputum (26.9% vs. 3.3%, $p < 0.001$).

With regard to the risk factors associated with MP acquisition, we compared baseline characteristics, underlying morbidity and use of antibiotics within 28 days prior to isolation between MPs and INMNPs (Table 2). ICU stay (70.1% vs. 25%, $p = 0.003$) and mechanical ventilator care prior to PA/AB isolation

Table 1. Characteristics of the Twelve Patients with MBL Producing Isolates

No.	Age (yrs)	Sex	Org	Spec	Diagnosis	H stay 6 M	Charlson index	APA	Previously used antibiotics	MBL type	Susceptibility						Outcome
											TZP	CFS	AZT	FQ	AG	CAZ	
1*	42	M	PA	SPT	ICH	18	1	0	None	VIM-2	S	R	S	R	R	I	Survival
2*	65	F	PA	UR	Quadriplegia	0	1	6	None	VIM-2	R	R	S	R	I	R	Survival [†]
3	45	M	PA	SPT	Pulmonary tbc.	180	1	6	MER, CIP, VAN, AMP/S	VIM-2	R	R	I	R	R	R	Survival
4	52	F	PA	UR	Gastric cancer	20	6	3	CEP, ISE	VIM-2	S	R	R	R	R	S	Survival
5	60	F	PA	SPT	CRF	1	2	11	None	IMP-1	S	R	R	R	S	R	Survival
6	3	F	PA	UR	Pneumonia	4	0	1	CLA	VIM-2	R	R	I	R	S	I	Survival
7	88	M	PA	UR	Pancreatic cancer	54	6	14	None	VIM-2	R	R	R	I	S	R	Death
8	66	M	AB	SPT	Lung cancer	20	2	8	CFT, MER, ISE, VAN	VIM-2	S	S	I	S	R	R	Survival
9	74	M	AB	SPT	Acute cholecystitis	73	2	8	TZP, CLI	VIM-2	S	S	I	S	R	R	Survival
10	12	M	AB	UR	ALL	29	2	4	None	SIM-1	R	I	R	S	S	R	Survival
11	7	F	AB	SPT	Kawasaki disease	4	0	17	AMO/C, TEI	IMP-1	I	S	I	S	S	R	Death
12	55	M	AB	UR	CHF	11	1	7	CZL, AMK, VAN	VIM-2	I	S	R	S	R	R	Survival

MBL, metallo-β-lactamase; Org, organism; Spec, Specimen; H stay 6 M, Hospital stay within 6 months prior to isolation including multiple admissions; APA, APACHE II Score; TZP, piperacillin/tazobactam; CFS, ceftazidime; AZT, aztreonam; FQ, fluoroquinolones; AG, aminoglycoside; CAZ, ceftazidime; PA, *Pseudomonas aeruginosa*; AB, *Acinetobacter baumannii*; SPT, sputum; UR, urine; ICH, intracranial hemorrhage; Pulmonary tbc., pulmonary tuberculosis; CRF, chronic renal failure; ALL, acute lymphocytic leukemia; CHF, congestive heart failure; CIP, ciprofloxacin; AMP/S, ampicillin/sulbactam; CEP, cefepime; CLA, clarithromycin; CFT, ceftriaxone; MER, meropenem; ISE, isepamicin; VAN, vancomycin; CL, clindamycin; AMO/C, amoxicillin/clavulanate; TEI, teicoplanin; CZL, ceftazolin; AMK, amikacin; S, susceptible; R, resistant; I, intermediate.

*Two isolates revealed identical PFGE patterns and they were inpatient and outpatient of the same center.

[†]Patient no. 2 regularly visited the outpatient department up to six months after the isolation, and was considered as a survival case.




Fig. 1. Pulsed field gel electrophoresis (PFGE) analysis of metallo- β -lactamase (MBL)-producing *Pseudomonas aeruginosa* (A) and *Acinetobacter baumannii* (B). Two isolates of *Pseudomonas aeruginosa* (case no. 1 and no. 2) revealed identical patterns. One of them was an inpatient and the other an outpatient of the same center. The numbers on top of each figure refer to the case numbers described in Table 1. Lane M, molecular weight marker (kb).

(56.6% vs. 25%, $p = 0.034$) were more frequent in the INMNP group. Exposure to antibiotics was also more frequent in the INMNP group (76.2% vs. 41.7%, $p = 0.015$). In the analysis of individual antibiotics, exposure to piperacillin/tazobactam was significantly more frequent in the INMNP group. Therefore, it was not possible to identify significant risk factor related with MP acquisition among imipenem nonsusceptible isolate acquired patients. Twenty-eight-day and in-hospital case-fatality after imipenem nonsusceptible isolates acquisition revealed no difference between MPs and INMNPs.

With regard to the susceptibilities to the six antibiotics which were frequently used for treatment of PA and AB other than carbapenem (Table 3), the proportions of susceptible isolates were higher in the MP group for more than half of the analyzed drugs, and those of piperacillin/tazobactam and fluoroquinolones showed statistically significant differences. Regarding to ceftazidime, only one strain (8.3%) was susceptible among MPs, and this proportion was significantly lower than that of INMNPs (61.7%), which is comparable with previous report.¹² However, the aztreonam susceptibility which is known to be uniquely spared among β -lactams against MBL was preserved in only 2 isolates (16.7%) among MPs, and it was not more frequent than that of INMNPs (23.2%).

As mentioned above, the clinical data concerning risk factors and treatment outcomes of infections caused by

MBL-producing strains are sparse. Analysis of the antimicrobial chemotherapy administered before isolation of MPs often revealed that many patients had not been administered with carbapenems, but fluoroquinolones^{3,13} and β -lactam antibiotics.^{3,14,15} Other reports suggested carbapenem use, ICU stay > 20 days,¹⁵ underlying neurologic disorder, urinary tract infection, renal failure,³ and neutropenia¹⁴ as contributing factors. However, all of the above mentioned studies compared an MP group with an MNP group irrespective of the susceptibility to carbapenems, which are now considered as a key drug for the treatment of gram-negative bacilli due to the apparently high barrier to resistance acquisition. Therefore, we chose to compare an MP group with an INMNP group rather than with a mere MNP group that includes carbapenem susceptible isolates. Although we failed to identify any significant risk factor, this result might be related to the limited number of MPs in our study population. Further investigation is required to explain this aspect.

We could not investigate the MP acquisition-related mortality because our cases included not only clinical infections, but also colonization. Some authors^{2,4,5} have reported higher mortality in an MP group. However, they compared the group with MNPs irrespective of carbapenem sensitivity. Although Laupland, et al.¹⁶ observed higher mortality in MBL-producing PA infected patients than in the MBL-non-producing carbapenem resistant group, more data are required to ascertain the impact of MBL acquisition on mortality. In a recent study, for example, carbapenem resistance, advanced age, and severity of underlying disease were suggested as independent risk factors for mortality, but not VIM-1 type MBL production among *Klebsiella pneumoniae* bloodstream infection patients.¹⁷

As regards to the susceptibility of antibiotics other than imipenem, aztreonam is generally an exception, while MBL production results in high-level resistance to most β -lactam antibiotics. However, equivalent resistance profiles for aztreonam have been observed between the MP group and the MNP group in previous reports.^{3,18,19} Our study also revealed higher percentage of resistance to aztreonam in the MP group. Resistance to aztreonam in MPs might be explained by extended spectrum β -lactamases (ESBL),^{20,21} AmpC β -lactamases,²²⁻²⁴ or other non-enzymatic mechanisms²³ as described before. Therefore, aztreonam may not be an exceptionally useful β -lactam antibiotic for the treatment of MPs in current clinical settings.

The portion of strains showing susceptibility for piper-

acillin/tazobactam and fluoroquinolones were higher among MPs, and overall prior antibiotics exposure was more frequent in the INMNP group. These findings are not consistent with previous reports,^{3,16,18} and the discrepancies might

be related to our study group which included not only patients with clinical infections but also patients with colonization.

In PFGE analysis, two isolates which were obtained 14

Table 2. Comparison between MBL-Producers and MBL-Nonproducers

	MBL-nonproducers n = 164 (93.2)	MBL-producers n = 12 (6.8)	p value
Mean age (yrs)	55.19	47.42	0.353
Male sex	112 (68.3)	7 (58.3)	0.529
Hospital stay within 6 months (days)*	38.62	34.58	0.793
Species			
<i>Pseudomonas aeruginosa</i>	116 (70.7)	7 (58.3)	
<i>Acinetobacter baumannii</i>	48 (29.3)	5 (41.7)	0.350
Charlson index (mean)	2.15	2.00	0.803
APACHE II score (mean)	9.79	7.08	0.100
Underlying disease			
Malignancy	41 (25.0)	4 (33.3)	0.506
Diabetes mellitus	46 (28.0)	2 (16.7)	0.519
Renal disease	24 (14.6)	1 (8.3)	0.455
Cardiac disease	33 (20.2)	2 (16.7)	1.000
Liver cirrhosis	9 (5.5)	0	1.000
Neutropenia	3 (3.1)	0	1.000
Immunosuppression	32 (19.6)	5 (41.7)	0.133
ICU stay	115 (70.1)	3 (25)	0.003
Ventilator care	91 (56.6)	3 (25)	0.034
Previous antibiotics exposure	119 (72.6)	5 (41.7)	0.015
Piperacillin/tazobactam	43 (26.2)	0	0.040
Cefoperazone/sulbactam	29 (17.7)	0	0.220
Aztreonam	2 (1.2)	0	1.000
Fluoroquinolones	63 (38.4)	2 (16.7)	0.215
Aminoglycosides	42 (25.6)	3 (25)	1.000
Glycopeptides	78 (47.6)	3 (25)	0.148
Ceftazidime	15 (9.1)	0	0.603
Carbapenem	56 (34.1)	2 (16.7)	0.341
28-day case-fatality	26 (15.6)	1 (8.3)	0.696
In hospital case-fatality	59 (36.0)	2 (16.7)	0.221

MBL, metallo- β -lactamase; ICU, intensivecareunit.

*All hospital stay duration within 6 months prior to imipenem nonsusceptible organism isolation were added including multiple admissions. The data are the numbers (%) of patients unless otherwise indicated.

Table 3. Susceptibility to Antibiotics Other Than Carbapenem

	MBL-nonproducers n = 164 (93.2)	MBL-producers n = 12 (6.8)	p value
Piperacillin/tazobactam	27 (16.5)	5 (41.7)	0.045
Cefoperazone/sulbactam	35 (21.3)	4 (33.3)	0.305
Aztreonam	38 (23.2)	2 (16.7)	1.000
Fluoroquinolones	20 (12.2)	5 (41.7)	0.015
Aminoglycosides	51 (31.1)	5 (41.7)	0.524
Ceftazidime	102 (62.2)	1 (8.3)	< 0.001

MBL, metallo- β -lactamase.

The data are the numbers (%) of patients unless otherwise indicated.

days apart revealed identical PFGE patterns in 7 MBL producing PA. A direct contact between the two patients was not identified. However, one source of major concern is the ability of MBLs to spread rapidly which has been observed in various clinical circumstances.^{2,25,26} The above cases could be an example of the potential clonal spread of MPs, although the majority of MPs occurred sporadically in our institution, and contribution of MBL to carbapenem resistance was limited, similar to other study performed in the same country.²⁷

In conclusion, the contribution of MBL to imipenem resistance in PA/AB isolated from sputum and urine was relatively limited in our institution, and there was no identifiable risk factor associated with MPs acquisition, compared with INMNPs. However, the limited susceptibility to aztreonam in the MP group implies that MBL producing strains commonly carry other resistance mechanisms such as ES-βLs, AmpC β-lactamases, and other non-enzymatic mechanisms.

Our study has several limitations. First, the number of MPs used for the study was small, and that could have impaired our ability to identify significant risk factors associated with acquisition of MPs. Subgroup analysis according to isolation sources was also not feasible because of the small size of the population under investigation. Second, we included all isolates from the respiratory and urinary tract, therefore, our results might not be generalized as overt clinical infections. Further analysis of a significant number of infection cases is required to more accurately assess the clinical impact of MPs.

ACKNOWLEDGEMENTS

This work was supported by the grant of Intramural Fund of Korea National Institute of Health and Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A084063).

REFERENCES

- Cornaglia G, Akova M, Amicosante G, Cantón R, Cauda R, Docquier JD, et al. Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. *Int J Antimicrob Agents* 2007;29:380-8.
- Zavascki AP, Barth AL, Gonçalves AL, Moro AL, Fernandes JF, Martins AF, et al. The influence of metallo-beta-lactamase production on mortality in nosocomial *Pseudomonas aeruginosa* infections. *J Antimicrob Chemother* 2006;58:387-92.
- Zavascki AP, Barth AL, Gaspareto PB, Gonçalves AL, Moro AL, Fernandes JF, et al. Risk factors for nosocomial infections due to *Pseudomonas aeruginosa* producing metallo-beta-lactamase in two tertiary-care teaching hospitals. *J Antimicrob Chemother* 2006;58:882-5.
- Hirakata Y, Yamaguchi T, Nakano M, Izumikawa K, Mine M, Aoki S, et al. Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing *Pseudomonas aeruginosa*. *Clin Infect Dis* 2003;37:26-32.
- Zavascki AP, Barth AL, Fernandes JF, Moro AL, Gonçalves AL, Goldani LZ. Reappraisal of *Pseudomonas aeruginosa* hospital-acquired pneumonia mortality in the era of metallo-beta-lactamase-mediated multidrug resistance: a prospective observational study. *Crit Care* 2006;10:R114.
- Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among *Pseudomonas aeruginosa* isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. *Infect Control Hosp Epidemiol* 2006;27:893-900.
- Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, et al. Impact of imipenem resistance on mortality in patients with *Acinetobacter bacteraemia*. *J Antimicrob Chemother* 2007;59:525-30.
- Murray EJ, Baron EJ, Pfaller MA, Tenover FC, Tenover RH. *Manual of clinical microbiology*. 7th ed. Washington DC: ASM Press; 1999. p.442-58.
- Performance standards for antimicrobial susceptibility testing; Nineteenth Informational Supplement. 2009;CLSI document M100-S19.
- Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of *Pseudomonas* spp. and *Acinetobacter* spp. *J Clin Microbiol* 2003;41:4623-9.
- Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, et al. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from *Acinetobacter baumannii* clinical isolates from Korea. *Antimicrob Agents Chemother* 2005;49:4485-91.
- Lee K, Ha GY, Shin BM, Kim JJ, Kang JO, Jang SJ, et al. Metallo-beta-lactamase-producing Gram-negative bacilli in Korean Nationwide Surveillance of Antimicrobial Resistance group hospitals in 2003: continued prevalence of VIM-producing *Pseudomonas* spp. and increase of IMP-producing *Acinetobacter* spp. *Diagn Microbiol Infect Dis* 2004;50:51-8.
- Nouér SA, Nucci M, de-Oliveira MP, Pellegrino FL, Moreira BM. Risk factors for acquisition of multidrug-resistant *Pseudomonas aeruginosa* producing SPM metallo-beta-lactamase. *Antimicrob Agents Chemother* 2005;49:3663-7.
- Kim YA, Choi JY, Kim CK, Kim CO, Kim MS, Choi SH, et al. Risk factors and outcomes of bloodstream infections with metallo-beta-lactamase-producing *Acinetobacter*. *Scand J Infect Dis* 2008;40:234-40.
- Horianopoulou M, Legakis NJ, Kanellopoulou M, Lambropoulos S, Tsakris A, Falagas ME. Frequency and predictors of colonization of the respiratory tract by VIM-2-producing *Pseudomonas aeruginosa* in patients of a newly established intensive care unit. *J Med Microbiol* 2006;55:1435-9.
- Laupland KB, Parkins MD, Church DL, Gregson DB, Louie TJ, Conly JM, et al. Population-based epidemiological study of infections caused by carbapenem-resistant *Pseudomonas aeruginosa* in

- the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains. *J Infect Dis* 2005;192:1606-12.
17. Daikos GL, Petrikos P, Psychogiou M, Kosmidis C, Vryonis E, Skoutelis A, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with *Klebsiella pneumoniae* bloodstream infections. *Antimicrob Agents Chemother* 2009;53:1868-73.
 18. Huang YT, Chang SC, Lauderdale TL, Yang AJ, Wang JT. Molecular epidemiology of carbapenem-resistant *Pseudomonas aeruginosa* carrying metallo-beta-lactamase genes in Taiwan. *Diagn Microbiol Infect Dis* 2007;59:211-6.
 19. Doi Y, Ghilardi AC, Adams J, de Oliveira Garcia D, Paterson DL. High prevalence of metallo-beta-lactamase and 16S rRNA methylase coproduction among imipenem-resistant *Pseudomonas aeruginosa* isolates in Brazil. *Antimicrob Agents Chemother* 2007;51:3388-90.
 20. Pasteran F, Faccone D, Petroni A, Rapoport M, Galas M, Vázquez M, et al. Novel variant (bla(VIM-11)) of the metallo-β-lactamase bla(VIM) family in a GES-1 extended-spectrum-β-lactamase-producing *Pseudomonas aeruginosa* clinical isolate in Argentina. *Antimicrob Agents Chemother* 2005;49:474-5.
 21. Yong D, Shin JH, Kim S, Lim Y, Yum JH, Lee K, et al. High prevalence of PER-1 extended-spectrum-beta-lactamase-producing *Acinetobacter* spp. in Korea. *Antimicrob Agents Chemother* 2003;47:1749-51.
 22. Segal H, Nelson EC, Elisha BG. Genetic environment and transcription of ampC in an *Acinetobacter baumannii* clinical isolate. *Antimicrob Agents Chemother* 2004;48:612-4.
 23. Cavallo JD, Fabre R, Leblanc F, Nicolas-Chanoine MH, Thabaut A; Group d'Etude de la Résistance de *Pseudomonas aeruginosa* aux Bêtalactamines. Antibiotic susceptibility and mechanisms of beta-lactam resistance in 1310 strains of *pseudomonas aeruginosa*: a French multicentre study (1996). *J Antimicrob Chemother* 2000;46:133-6.
 24. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in *Acinetobacter baumannii* clinical strains. *J Antimicrob Chemother* 2003;52:629-35.
 25. Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. *Clin Infect Dis* 2005;41:1549-56.
 26. Fukigai S, Alba J, Kimura S, Iida T, Nishikura N, Ishii Y, et al. Nosocomial outbreak of genetically related IMP-1 beta-lactamase-producing *Klebsiella pneumoniae* in a general hospital in Japan. *Int J Antimicrob Agents* 2007;29:306-10.
 27. Lee K, Kim MN, Choi TY, Cho SE, Lee S, Whang DH, et al. Wide dissemination of OXA-type carbapenemases in clinical *Acinetobacter* spp. isolates from South Korea. *Int J Antimicrob Agents* 2009;33:520-24.